^
    Back
    Association details:
    Biomarker:NPM1 expression
    Cancer:Acute Myelogenous Leukemia
    Drug:revumenib (SNDX-5613) (Menin-MLL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2021
    Title:

    Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models

    Published date:
    11/04/2021
    Excerpt:
    SNDX-50469 or SNDX-5613 treatment also exhibits impressive in vivo anti-AML efficacy in AML models expressing MLL-FP and NPM1c.
    DOI:
    10.1182/blood-2021-152060